Unknown PHASE2 INTERVENTIONAL 1-arm NCT00856804

Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance (TRITAL)

Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II

Sponsor: University of Seville

Conditions Hepatitis C

Interventions thalidomide

Updated 6 times since 2017 Last updated: Mar 5, 2009 Started: Mar 31, 2009 Primary completion: Jun 30, 2009 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hepatitis C, this trial is ongoing. The trial is conducted by University of Seville and has accumulated 6 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Seville
Valme University Hospital

Data source: Valme University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seville, Spain